查看所有供应商和价格请点击:
1622075-65-3生产厂家
1622075-65-3价格
化源商城直购
[1]. Robert J Kreitman, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.
[2]. Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767.